Live Roundups Editor's Desk Insights Executive Ops Weather About 🔍
Home › Business & Finance › Collins ready for 'sink or swim' return after pain of...
Business & Finance

Collins ready for 'sink or swim' return after pain of missing title shot

Collins ready for 'sink or swim' return after pain of missing title shot
BBC Scotland Friday 25 September 2026, 10:24 UTC 1 min read
Key Points

Nathaniel Collins says the first loss of his career has taught him the importance of patience in the ring as he prepares to fight Liam Davies on Saturday.

Nathaniel Collins says the first loss of his career has taught him the importance of patience in the ring as he prepares to fight Liam Davies on Saturday.
Collins (PERSON) Nathaniel Collins (PERSON) Liam Davies (PERSON)
Originally published by BBC Scotland Read original →

Related Stories

Boost for savers as cash ISA rates hit key milestone and 15-month high

Boost for savers as cash ISA rates hit key milestone and 15-month high 5% interest is achievable in easy access accounts, but now for tax-free savings too - Bookmark - CommentsGo to comments Become an Independent member to bookmark this article Already a member? Log in Tax-free savings have hit a new milestone this week, with cash ISAs returning to 5 per cent rates for the first time in well over a year. The higher interest rate environment is a double-edged sword in some ways, given it...

The Independent UK 8m ago

NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have.

CNBC Cures is proudly underwritten by Alexion, AstraZeneca Rare Disease, whose support enables our journalism to elevate stories that advance research, innovation and patient care in rare diseases. John Paul Macri was a healthy, happy 8-year-old when early last year he began to trip. At first, his parents thought he was just clumsy.

CNBC 12m ago

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

Every time Novo urges investors to look ahead, Eli Lilly gives them another reason to look back at its widening lead over the Danish drugmaker. Novo this week laid out an ambitious strategy to reignite growth beyond its top-selling Wegovy and Ozempic injections, which face patent expirations in key markets in the early 2030s. At its Capital Markets Day on Monday, the company promised a pipeline of potential blockbuster products, including drugs that would diversify from its core area of...

CNBC 12m ago

Why this Pokémon set is dropping in value

How does one price a cemetery plot? Are they using dynamic pricing to figure it out? We tackle that question and many more in this week's Indicator newsletter.(Image credit: Pokémon/Nintendo/Creatures/GAME FREAK.)

NPR Business 12m ago